Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05990296 · ClinicalTrials.gov registry record · NA
Evaluating Strategies to Improve Guideline Directed Medical Therapy: The GDMT Research, Education & Assist Trial for Heart Failure Care
A NA study of Heart Failure and Heart Failure With Reduced Ejection Fraction, sponsored by Geisinger Clinic.
- Completed
- Registry status
- NA
- Development phase
- 4,306
- Enrollment target
- 1
- Study location
NCT05990296: Completed NA study of Heart Failure and Heart Failure With Reduced Ejection Fraction, sponsored by Geisinger Clinic.
NCT05990296 is a NA study of Heart Failure and Heart Failure With Reduced Ejection Fraction that has completed, run by Geisinger Clinic. The registered enrollment target is 4,306 participants, above the 2,038-participant average among 397 other Heart Failure trials with a reported enrollment target (111% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05990296, a NA study of Heart Failure and Heart Failure With Reduced Ejection Fraction, has completed, sponsored by Geisinger Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 4,306 participants
- Enrollment target
- 1
- Study location
Study Summary
Heart failure with reduced ejection fraction (HFrEF) is associated with high mortality and adverse events (hospitalization or urgent outpatient visits for HF), along with diminished quality of life. Despite convincing data that evidenced-based, guideline-directed medical therapies (GDMT) improve mortality and heart failure-related events, there remains insufficient utilization of these life-saving drugs (evidence-based beta-blockers (EBBB), angiotensin-neprilysin inhibitors (ARNI)/ angiotensin converting enzyme inhibitors (ACEi)/ angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists (MRA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with HFrEF. The primary objective of this study is to implement and evaluate a multifaceted, interdisciplinary intervention to improve GDMT use, reduce mortality, and reduce future heart failure events in patients with HFrEF.
Primary Outcome
New GDMT HF medication class added, switch to ARNI from ACE/ARB, or upward dose titration of existing GDMT HF medication.
Conditions Studied
Interventions
- BEHAVIORAL Multiprong CDS with referral to pharmacist co-management
- BEHAVIORAL Multiprong CDS with GDMT order set
- BEHAVIORAL Focused education
Study Locations (1)
Pennsylvania
- Geisinger Cardiology Clinics - Danville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,306 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2025-05-17 |
| Phase | NA |
What the finished NCT05990296 record still lists
NCT05990296 is an interventional study that assigns participants to a tested intervention. Its 4,306 participants enrollment target places it among the larger protocols in the corpus, above the 2,038-participant average among 397 other Heart Failure trials with a reported enrollment target (111% higher).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Multiprong CDS with referral to pharmacist co-management is the first listed.
NCT05990296 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05990296 about?
NCT05990296 is a clinical study titled "Evaluating Strategies to Improve Guideline Directed Medical Therapy: The GDMT Research, Education & Assist Trial for Heart Failure Care". Heart failure with reduced ejection fraction (HFrEF) is associated with high mortality and adverse events (hospitalization or urgent outpatient visits for HF), along with diminished quality of life. Despite convincing data that evidenced-based, guideline-directed medical therapies (GDMT) improve mor...
What is the current status of trial NCT05990296?
This trial is currently completed. It is a NA study. The enrollment target is 4,306 participants. The study started on 2023-08-01. Estimated completion is 2025-05-17.
What conditions does trial NCT05990296 study?
This clinical trial studies the following conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction.
What interventions are being tested in trial NCT05990296?
The interventions under investigation include: Multiprong CDS with referral to pharmacist co-management (BEHAVIORAL), Multiprong CDS with GDMT order set (BEHAVIORAL), Focused education (BEHAVIORAL).
Who is sponsoring clinical trial NCT05990296?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05990296 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05990296's enrollment target sits among peer trials
4,306 25th of 397 higher than 373 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- NCT05543616 · 4,292 participants · Phase 2
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
- NCT05910567 · 4,346 participants · NA
A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma
- NCT07044297 · 4,390 participants · Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI